Welcome to our dedicated page for Adma Biologics SEC filings (Ticker: ADMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the line that explains how many liters of high-titer plasma ADMA Biologics turns into specialty immunoglobulin each quarter? Start your research here. Our SEC dashboard pulls every filing—10-K annual reports, 10-Q quarterly earnings updates, Form 4 insider trading notices, 8-K material events—within minutes of hitting EDGAR, so you never miss an FDA update or production metric.
Use Stock Titan’s AI to skim a 250-page report in seconds. The platform highlights where management discusses manufacturing capacity, cash runway, and regulatory milestones, turning understanding ADMA Biologics SEC documents with AI into a two-click task. Need the latest ADMA Biologics quarterly earnings report 10-Q filing? It’s tagged and summarized, complete with segment revenue trends and yield-per-liter calculations. Tracking ownership shifts? Real-time alerts flag every ADMA Biologics Form 4 insider transactions so you can gauge executive confidence before news breaks.
Whether you’re comparing R&D spend across periods, monitoring an 8-K announcing new FDA correspondence, or dissecting the ADMA Biologics proxy statement executive compensation tables, our coverage is exhaustive and our explanations clear. Investors routinely watch ADMA Biologics insider trading Form 4 transactions for cues around trial read-outs, and analyze the ADMA Biologics annual report 10-K simplified to understand long-term supply-chain strategy. Stop wading through dense biotech jargon; let AI surface the insights that shape informed decisions.
Form 4 overview: ADMA Biologics (ticker ADMA) disclosed that Chief Financial Officer & Treasurer Brad L. Tade had 9,838 common shares withheld on 06/26/2025 (transaction code “F”). The “F” code means the shares were automatically surrendered to the company to satisfy statutory tax-withholding obligations triggered by the vesting of previously granted restricted stock units (RSUs); it was not an open-market sale.
Post-transaction holdings: Tade’s stated beneficial ownership is 246,542 shares after the withholding event. This figure comprises:
- 186,127 unvested RSUs spread across four grant dates (June 2023, Feb 2024, July 2024, Feb 2025) that vest quarterly over four years, contingent on continued employment.
- 24,415 fully vested shares accumulated through open-market purchases and past RSU settlements.
- The remaining balance represents fully vested shares already held.
No derivative activity was reported in Table II, and there were no purchases or sales of stock options or other instruments.
Investor takeaway: The filing is routine and signals mandatory tax withholding rather than discretionary selling. Insider equity alignment remains intact; the CFO continues to hold a meaningful stake that will grow as RSUs vest.
ADMA Biologics (ADMA) President and CEO Adam S. Grossman reported multiple transactions on June 16, 2025, executed under a pre-established Rule 10b5-1 trading plan from December 2024. The transactions included:
- Exercise of stock options for 15,000 shares at $5.40 per share
- Sale of 21,000 total shares at $20.81 per share
- Post-transaction direct ownership of 2,043,850 shares
- Indirect ownership of 1,143,426 shares through Areth LLC and 580,957 shares through Hariden LLC
Grossman maintains significant equity positions including unvested RSUs totaling over 1 million shares granted between 2022-2025, vesting quarterly over four years. He also holds 810,950 stock options granted February 2024 at $5.40/share, vesting through February 2028. The transactions demonstrate a routine exercise-and-sell pattern while maintaining substantial long-term ownership.
FAQ
What is the current stock price of Adma Biologics (ADMA)?
What is the market cap of Adma Biologics (ADMA)?
What is the primary focus of ADMA Biologics?
How does ADMA generate revenue?
What distinguishes ADMA in the biopharmaceutical industry?
What role do plasma collection centers play in the company’s operations?
How does the company ensure regulatory compliance and product quality?
Are there any unique storage or handling features for ADMA's products?
How is ADMA positioned compared to other companies in its market?
